Phaseline

Companies › Mercator MedSystems

Mercator MedSystems: clinical trials, targets and expected readouts

1 active drug program in 8 registered trials: 4 Phase 1, 2 Phase 3, 2 Phase 2; Cardiovascular, Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Temsirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Peripheral Artery Disease; Alveolar Rhabdomyosarcoma; Advanced Rare Tumours; Endometrial Adenocarcinoma …Feb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02567435TemsirolimusPhase 3Alveolar RhabdomyosarcomaOncologyJun 2023
NCT01087554TemsirolimusPhase 1Advanced CancerOncologyAug 2026
NCT01396408TemsirolimusPhase 2Advanced Rare TumoursOncologyDec 2026
NCT00977574TemsirolimusPhase 2Endometrial AdenocarcinomaOncologyMar 2027
NCT01375829TemsirolimusPhase 1Adult Solid NeoplasmOncologyMar 2027
NCT02389309TemsirolimusPhase 1Advanced Malignant Solid NeoplasmOncologyOct 2027
NCT04433572TemsirolimusPhase 3Peripheral Artery DiseaseCardiovascularFeb 2028
NCT01187199TemsirolimusPhase 1Advanced CancerOncologyApr 2028

Targets

FKBP1A (1)

Companies with the same targets

Eisai CSPC ZhongQi Pharmaceutical Technology Restorbio Novartis Rapamycin Holdings AgelessRx Novaliq Palvella Therapeutics Jiangsu Simcere Pharmaceutical Aadi Bioscience

Companies built like this

Rapamycin Holdings Aadi Bioscience Ablative Solutions Novaliq Guerbet

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.